Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.37 |
| ▸ | CYP8B1 | Q9UNU6 | 4/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3850897 | 0.99 | CHRM4 (0.40) | CHRM4NCF1LRRK2CYP8B1PIK3CA | |
| Hydrochloric Acid SCHEMBL3856763 | 0.94 | CHRM4 (0.43) | CHRM4NCF1LRRK2CYP8B1PIK3CA | |
| SCHEMBL3767256 | 0.87 | CHRM4 (0.43) | CHRM4NCF1LRRK2PIK3CACYP2C19 | |
| Hydrochloric Acid SCHEMBL3845747 | 0.86 | CHRM4 (0.42) | CHRM4NCF1LRRK2PIK3CACYP2C19 | |
| SCHEMBL3851844 | 0.81 | CYP3A4 (0.50) | CHRM4NCF1CYP8B1PIK3CA | |
| SCHEMBL3854617 | 0.81 | CHRM4 (0.47) | CHRM4NCF1CYP8B1PIK3CA | |
| SCHEMBL13874431 | 0.81 | CHRM4 (0.46) | CHRM4NCF1LRRK2PIK3CACYP2C19 | |
| Hydrochloric Acid SCHEMBL4717123 | 0.80 | CHRM4 (0.46) | CHRM4NCF1CYP8B1PIK3CA | |
| Hydrochloric Acid SCHEMBL3849538 | 0.80 | CHRM4 (0.46) | CHRM4NCF1LRRK2PIK3CACYP2C19 | |
| SCHEMBL3852542 | 0.80 | GAA (0.51) | NCF1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | ARG1, LPO, CTSL | CHRM4 1206/4885NCF1 892/4885LRRK2 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.